Overall rank by patents
#25,924
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
Boreal holds 10 US patents across 5 technology areas, rank #25,924 of 50,000 tracked assignees.
Boreal Genomics, Inc. has been granted 10 US utility patents between 2015 and 2022, placing Boreal Genomics, Inc. at rank #25,924 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.7 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Boreal Genomics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Boreal sits between Bocks Inc. (10 patents, rank #25,920) and Breakthrough Technologies, Llc (10 patents, rank #25,928) - the closest US assignees by grant volume. The composite Innovation Score of 26.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 4 in the 2015–2019 window, a +50% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Boreal Genomics, Inc.'s 15.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Boreal Genomics, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Bocks Inc.
10 patents
BodyMedia, Inc.
10 patents
Bond Formwork Systems, LLC
10 patents
BooginHead LLC
10 patents
Bosch Rexroth Corporation
10 patents
Boveda Inc.
10 patents
Brak Tub Corp.
10 patents
Breakthrough Technologies, LLC
10 patents
Boreal Genomics, Inc.
10 patents
What this shows Boreal holds 10 patents at rank #25,924, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Boreal's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 78% higher than 22% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 10.0% |
| 2016 | 2 | 20.0% |
| 2018 | 1 | 10.0% |
| 2020 | 2 | 20.0% |
| 2021 | 3 | 30.0% |
| 2022 | 1 | 10.0% |
Top 5 of 5 technology areas
Overall rank by patents
#25,924
Across all tracked assignees
26.9 out of 100
How to use this portfolio
Boreal's 10 grants land it in the top 78% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.